Search

Your search keyword '"Pierdomenico, Sante Donato"' showing total 28 results
Start Over Author "Pierdomenico, Sante Donato"
28 results on '"Pierdomenico, Sante Donato"'

6. Predictors of Mortality and Cardiovascular Outcome at 6 Months after Hospitalization for COVID-19

Author

Renda, Giulia, primary, Ricci, Fabrizio, additional, Spinoni, Enrico Guido, additional, Grisafi, Leonardo, additional, D’Ardes, Damiano, additional, Mennuni, Marco, additional, Tana, Claudio, additional, Rognoni, Andrea, additional, Bellan, Mattia, additional, Sainaghi, Pier Paolo, additional, Pirisi, Mario, additional, De Vecchi, Simona, additional, Gallina, Sabina, additional, Pierdomenico, Sante Donato, additional, Cipollone, Francesco, additional, and Patti, Giuseppe, additional

Published
2022
Full Text
View/download PDF

7. 606 Predictive value of left atrial and left ventricular strain for the detection of atrial fibrillation in patients with cryptogenic stroke

Author

Bufano, Gabriella, primary, Radico, Francesco, additional, D’Angelo, Carolina Maria, additional, Pierfelice, Francesca, additional, Vittoria De Angelis, Maria, additional, Faustino, Massimiliano, additional, Pierdomenico, Sante Donato, additional, Gallina, Sabina, additional, and Renda, Giulia, additional

Published
2021
Full Text
View/download PDF

9. Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19

Author

Spinoni, Enrico Guido, primary, Mennuni, Marco, additional, Rognoni, Andrea, additional, Grisafi, Leonardo, additional, Colombo, Crizia, additional, Lio, Veronica, additional, Renda, Giulia, additional, Foglietta, Melissa, additional, Petrilli, Ivan, additional, D’Ardes, Damiano, additional, Sainaghi, Pier Paolo, additional, Aimaretti, Gianluca, additional, Bellan, Mattia, additional, Castello, Luigi, additional, Avanzi, Gian Carlo, additional, Corte, Francesco Della, additional, Krengli, Marco, additional, Pirisi, Mario, additional, Malerba, Mario, additional, Capponi, Andrea, additional, Gallina, Sabina, additional, Pierdomenico, Sante Donato, additional, Cipollone, Francesco, additional, Patti, Giuseppe, additional, Albano, Emanuele, additional, Dianzani, Umberto, additional, Gaidano, Gianluca, additional, Gennari, Alessandra, additional, Gramaglia, Carla, additional, Solli, Martina, additional, Giubertoni, Ailia, additional, Veia, Alessia, additional, Cisari, Carlo, additional, Amedeo Tillio, Paolo, additional, Valletti, Paolo Aluffi, additional, Adesi, Francesco Barone, additional, Barini, Michela, additional, Ferrante, Daniela, additional, De Vecchi, Simona, additional, Santagostino, Matteo, additional, Acquaviva, Antonio, additional, Calzaducca, Elisa, additional, Casciaro, Francesco Giuseppe, additional, Ceruti, Federico, additional, Cittone, Micol Giulia, additional, Di Benedetto, Davide, additional, Gagliardi, Ileana, additional, Giacomini, Greta Maria, additional, Landi, Irene Cecilia, additional, Landi, Raffaella, additional, Manfredi, Giulia Francesca, additional, Pedrinelli, Anita Rebecca, additional, Rigamonti, Cristina, additional, Rizzi, Eleonora, additional, Smirne, Carlo, additional, Vassia, Veronica, additional, Arioli, Roberto, additional, Danna, Pietro, additional, Falaschi, Zeno, additional, Paschè, Alessio, additional, Percivale, Ilaria, additional, Zagaria, Domenico, additional, Beltrame, Michela, additional, Bertoli, Matteo, additional, Galbiati, Alessandra, additional, Gardino, Clara Ada, additional, Gastaldello, Maria Luisa, additional, Via, Valentina Giai, additional, Giolitti, Francesca, additional, Inserra, Ilaria, additional, Labella, Emanuela, additional, Nerici, Ilaria, additional, Gironi, Laura Cristina, additional, Cammarata, Edoardo, additional, Esposto, Elia, additional, Tarantino, Vanessa, additional, Zavattaro, Elisa, additional, Zottarelli, Francesca, additional, Daffara, Tommaso, additional, Ferrero, Alice, additional, Leone, Ilaria, additional, Nuzzo, Alessandro, additional, Baldon, Giulia, additional, Battistini, Sofia, additional, Chirico, Emilio, additional, Lorenzini, Luca, additional, Martelli, Maria, additional, Barbero, Emanuela, additional, Boffano, Paolo, additional, Brucoli, Matteo, additional, Garzaro, Massimiliano, additional, Pau, Alberto, additional, Bertolin, Stephanie, additional, Marzari, Letizia, additional, Avino, Gianluca, additional, Saraceno, Massimo, additional, Morosini, Umberto, additional, Baricich, Alessio, additional, Invernizzi, Marco, additional, Gallo, Silvia, additional, Montabone, Claudia, additional, Padelli, Samuel Alberto, additional, Boglione, Lucio, additional, Patrucco, Filippo, additional, Salamina, Luigia, additional, Baorda, Francesca, additional, Croce, Eleonora, additional, and Giacone, Irene, additional

Published
2021
Full Text
View/download PDF

12. Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway

Author

Madonna, Rosalinda, primary, Pieragostino, Damiana, additional, Cufaro, Maria Concetta, additional, Doria, Vanessa, additional, Del Boccio, Piero, additional, Deidda, Martino, additional, Pierdomenico, Sante Donato, additional, Dessalvi, Christian Cadeddu, additional, De Caterina, Raffaele, additional, and Mercuro, Giuseppe, additional

Published
2020
Full Text
View/download PDF

19. Association of serum bilirubin with oxidant damage of human atherosclerotic plaques and the severity of atherosclerosis.

Author

Lapenna, Domenico, Ciofani, Giuliano, Pierdomenico, Sante Donato, Giamberardino, Maria Adele, Ucchino, Sante, and Davì, Giovanni

Subjects
ATHEROSCLEROSIS, BILIRUBIN, ANTIOXIDANTS, LIPID peroxidation (Biology), ENDARTERECTOMY, BLOOD serum analysis, DIAGNOSIS
Abstract

Bilirubin has protective effects against atherosclerotic cardiovascular diseases hypothetically due to its antioxidant–antilipoperoxidative properties. Thus, we investigated whether serum bilirubin is associated with oxidant damage, namely lipid peroxidation, of human atherosclerotic plaques and the severity of atherosclerosis. In this regard, we correlated the levels of serum total bilirubin (STB), direct (conjugated) bilirubin (SDB) and indirect (unconjugated) bilirubin (SIB) with those of fluorescent damage products of lipid peroxidation (FDPL) and lipid hydroperoxides (LOOH) of 32 endarterectomy-derived carotid atherosclerotic plaques. Moreover, we compared the levels of serum bilirubin and plaque lipoperoxides between two groups of patients of the study population with different severity of atherosclerosis as judged by the carotid stenosis degree, i.e., <90% (group A, n = 23) and ≥90% (group B, n = 9). Remarkably, the levels of STB were strongly inversely correlated with those of plaque FDPL (rS = −0.70, P < 0.0001) and LOOH (rS = −0.66, P < 0.0001), as were those of SIB (FDPL: rS = −0.68, P < 0.0001; LOOH: rS = −0.63, P < 0.0001). SDB had a weaker association with plaque FDPL (rS = −0.41, P < 0.05) and LOOH (rS = −0.35, P < 0.05). Moreover, the levels of STB, SDB and SIB were lower and those of plaque lipoperoxides higher in group B than in group A, pointing to the association of serum bilirubin and plaque oxidant burden with the severity of atherosclerosis. In conclusion, lowered serum bilirubin is associated with oxidant damage of human atherosclerotic plaques and the severity of atherosclerosis. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

21. A prospective evaluation of iron deficiency anemia in the GI endoscopy setting: role of standard endoscopy, videocapsule endoscopy, and CT-enteroclysis

Author

Milano, Angelo, primary, Balatsinou, Chrysanthi, additional, Filippone, Antonella, additional, Caldarella, Maria Pia, additional, Laterza, Francesco, additional, Lapenna, Domenico, additional, Pierdomenico, Sante Donato, additional, Pace, Fabio, additional, Cuccurullo, Franco, additional, and Neri, Matteo, additional

Published
2011
Full Text
View/download PDF

26. Copper, zinc superoxide dismutase plus hydrogen peroxide: a catalytic system for human lipoprotein oxidation

Author

Lapenna, Domenico, Ciofani, Giuliano, Pierdomenico, Sante Donato, Giamberardino, Maria Adele, and Cuccurullo, Franco

Subjects
DISINFECTION & disinfectants, METALLOENZYMES, SOLUTION (Chemistry), SCAVENGERS (Zoology)
Abstract

We report for the first time that bovine or human CuZnSOD plus H2O2 can catalyze human lipoprotein oxidation, inducing like free copper ions a typical oxidative kinetics with lag and propagation phases. Free copper released from CuZnSOD by H2O2, but not enzyme peroxidase activity and carbonate radical anion, is responsible for lipoprotein oxidation, which is indeed totally inhibited by copper chelators and BHT but unaffected by bicarbonate. Moreover, lipoprotein oxidation is significantly counteracted by the OH scavengers formate and azide, which can enter the active site of CuZnSOD and decrease copper release through scavenging of copper-bound OH; benzoate and ethanol, which cannot enter, are instead ineffective, indicating no oxidative involvement of free OH escaped from the enzyme active site. The possibility of CuZnSOD/H2O2-catalyzed lipoprotein oxidation in vivo is discussed. [Copyright &y& Elsevier]

Published
2005
Full Text
View/download PDF

27. [Optimizing the care management pathway of patients with ischemia and non-obstructive coronary arteries].

Author

Oliva F, Boriani G, Calabrò P, Caldarola P, Carugo S, Castiglioni B, Celentani D, Comeglio M, De Luca L, De Maria R, Di Muro M, Ignone G, Leonardo F, Margonato A, Massari F, Murrone A, Nardi F, Patti G, Perna G, Pinna P, Poli M, Prati F, Raddino R, Pierdomenico SD, Tammaro P, and Porto I

Subjects
Humans, Coronary Vessels, Quality of Life, Ischemia, Heart, Myocardial Ischemia therapy, Coronary Artery Disease
Abstract

Ischemia with non-obstructive coronary arteries (INOCA) is defined by the coexistence of anginal symptoms and demonstrable ischemia, with no evidence of obstructive coronary arteries. The underlying mechanism of INOCA is coronary microvascular dysfunction with or without associated vasospasm. INOCA patients have recurrent symptoms, functional limitations, repeated access to the emergency department, impaired quality of life and a higher incidence of cardiovascular events than the general population. Although well described in chronic coronary syndrome guidelines, INOCA remains underdiagnosed in clinical practice because of insufficient awareness, lack of accurate diagnostic tools, and poorly standardized and consistent definitions to diagnose, both invasively and non-invasively, coronary microvascular dysfunction.To disseminate current scientific evidence on INOCA as a distinct clinical entity, during 2022 we conducted at 30 cardiology units all over the country a clinical practice improvement initiative, with the aim of developing uniform and shared management pathways for INOCA patients across different operational settings. The present document highlights the outcomes of this multidisciplinary initiative.

Published
2024
Full Text
View/download PDF

28. Upfront triple oral combination therapy including selexipag in a high-risk patient with idiopathic pulmonary arterial hypertension: a case report.

Author

Rossi S, Pietrangelo C, Pierdomenico SD, and Giuliani L

Abstract

Background: Selexipag is an oral selective prostacyclin IP receptor agonist approved in patients with low- and intermediate-risk pulmonary hypertension (PH); evidence in patients at high risk is lacking., Case Summary: A 42-year-old woman with worsening dyspnoea (World Health Organization functional class III-IV) and suspected PH at echocardiographic examination was evaluated in our Pulmonary Hypertension Centre. Right heart catheterization showed pre-capillary PH with reduced cardiac index and increased pulmonary vascular resistance. High-resolution computed tomography excluded parenchymal lung disease and ventilation/perfusion (V/Q) lung scan was negative for mismatched perfusion defects so the conclusive diagnosis was high-risk idiopathic pulmonary arterial hypertension (PAH). The patient refused an initial combination therapy including a parenteral prostacyclin analogue (PCA) in accordance with the ESC/ERS guidelines, so an off-label triple oral combination therapy including a phosphodiesterase-5 inhibitor, an endothelin receptor antagonist, and selexipag was started. At 3- and 6-month follow-up we found a clinical and haemodynamic improvement, so the patient was reclassified as low risk. Her clinical condition is currently stable., Discussion: Despite the benefit of parenteral PCAs in high-risk PAH, low adherence to treatment may be explained by adverse side effects related to the intravenous route of administration. Given the potential effect seen in our patient, upfront triple oral combination therapy in PAH high-risk patients should be further evaluated in a controlled clinical trial., (© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results